Is HBMHF or SCHD a better dividend investment in 2026?

HBMHF currently yields 128.21% with a 5% 5-year dividend growth rate. SCHD yields 3.44% with 13.05% growth. The better choice depends on your goal: HBMHF offers higher current income.

What is the dividend yield difference between HBMHF and SCHD?

HBMHF has a forward dividend yield of 128.21% ($2.00/share annually). SCHD yields 3.44% ($1.06/share annually). The yield gap is 124.77 percentage points.

Home › Compare › HBMHF vs SCHD

HBMHF vs SCHD: Dividend Comparison 2026

HBMHF yields 128.21% · SCHD yields 3.44%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 HBMHF wins by $11.57M in total portfolio value

INVESTMENT

TIME HORIZON10 years

HBMHF

● Live price

128.21%

Share price

$1.56

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$11.60M

Annual income

$4,575,129.27

Full HBMHF calculator →

SCHD

Schwab U.S. Dividend Equity ETF

● Live price

3.44%

Share price

$30.68

Annual div

$1.06

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$29.0K

Annual income

$422.61

Full SCHD calculator →

Portfolio growth — HBMHF vs SCHD

📍 HBMHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	HBMHF	SCHD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, HBMHF + SCHD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

HBMHF pays

SCHD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBMHF

Annual income on $10K today (after 15% tax)

$10,897.44/yr

After 10yr DRIP, annual income (after tax)

$3,888,859.88/yr

SCHD

Annual income on $10K today (after 15% tax)

$292.49/yr

After 10yr DRIP, annual income (after tax)

$359.22/yr

At 15% tax rate, HBMHF beats the other by $3,888,500.66/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBMHF + SCHD for your $10,000?

HBMHF: 50%SCHD: 50%

100% SCHD50/50100% HBMHF

Portfolio after 10yr

$5.81M

Annual income

$2,287,775.93/yr

Blended yield

39.36%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBMHF buys

SCHD buys

No recent congressional trades found for HBMHF or SCHD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricHBMHFSCHD

Forward yield	128.21% ✓	3.44%
Annual dividend / share	$2.00 ✓	$1.06
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$11.60M	$29.0K ✓
Annual income after 10y	$4,575,129.27 ✓	$422.61
Total dividends collected	$10.60M ✓	$3.9K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: HBMHF vs SCHD ($10,000, DRIP)

Year	HBMHF Portfolio	HBMHF Income/yr	SCHD Portfolio	SCHD Income/yr	Gap
1← crossover	$23,521	$12,820.51	$11,224	$344.10	+$12.3K → HBMHF
2	$53,349	$28,181.78	$12,567	$354.98	+$40.8K → HBMHF
3	$116,823	$59,739.54	$14,038	$365.30	+$102.8K → HBMHF
4	$247,259	$122,259.11	$15,648	$375.06	+$231.6K → HBMHF
5	$506,405	$241,837.18	$17,410	$384.27	+$489.0K → HBMHF
6	$1,004,750	$462,896.88	$19,335	$392.95	+$985.4K → HBMHF
7	$1,933,425	$858,342.70	$21,437	$401.10	+$1.91M → HBMHF
8	$3,612,406	$1,543,641.03	$23,733	$408.75	+$3.59M → HBMHF
9	$6,560,727	$2,695,452.74	$26,237	$415.91	+$6.53M → HBMHF
10	$11,595,107	$4,575,129.27	$28,968	$422.61	+$11.57M → HBMHF

HBMHF vs SCHD: Complete Analysis 2026

HBMHF — Stock

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry eye disease; HBM7008, a bispecific antibody targeting tumor Associated antigen; and HBM4003, a human anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4. The company is also developing HBM9022 for the treatment of SARS-COV-2; HBM9302 for the treatment of breast and gastric cancers; HBM7020 for the treatment of multiple myeloma; and HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022 for the treatment of solid tumors. It operates in Mainland China, the United States, Europe, and internationally. The company has collaboration on antibody-drug conjugate projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was incorporated in 2016 and is based in Shanghai, the People's Republic of China.

Full HBMHF Calculator →

SCHD — ETF

The fund’s goal is to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Dividend 100 Index.

Full SCHD Calculator →

📬

Get this HBMHF vs SCHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBMHF vs JEPI HBMHF vs O HBMHF vs KO HBMHF vs MAIN HBMHF vs VYM HBMHF vs DGRO HBMHF vs VIG HBMHF vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.